Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Naomi Winick, MD, Paul L. Martin, MD, PhD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, PhD, Paul Bowman, MD, Eric Larsen, MD, Jeanette Pullen, MD, Stephen P. Hunger, MD, William L. Carroll, MD, Bruce M. Camitta, MD

Blood (2007) 110 (11): 583.

https://doi.org/10.1182/blood.V110.11.583.583

Published: 2007

Journal Articles

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

Jeffrey Rubnitz, MD, PhD, David Wichlan, MS, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Joanne Kurtzberg, MD, Beverly Bell, MD, Stephen Hunger, MD, Allen Chauvenet, MD, Ching-Hon Pui, MD, Bruce Camitta, MD, Jeanette Pullen, MD

Blood (2006) 108 (11): 218.

https://doi.org/10.1182/blood.V108.11.218.218

Published: 2006

Journal Articles

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Beverly A. Bell, MD, Sharon B. Abish, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 875.

https://doi.org/10.1182/blood.V106.11.875.875

Published: 2005

Journal Articles

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Stephen Rodes, BS, Beverly A. Bell, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 882.

https://doi.org/10.1182/blood.V106.11.882.882

Published: 2005

Journal Articles

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Kirk R. Schultz, MD, Jeanette Pullen, MD, Harland Sather, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Paul S. Gaynon, MD, Bruce M. Camitta, MD

Blood (2004) 104 (11): 519.

https://doi.org/10.1182/blood.V104.11.519.519

Published: 2004

Journal Articles

Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study

Michael J. Borowitz, Jonathan Shuster, Andrew J. Carroll, Michael Nash, A. Thomas Look, Bruce Camitta, Donald Mahoney, Stephen J. Lauer, D. Jeanette Pullen

Blood (1997) 89 (11): 3960–3966.

https://doi.org/10.1182/blood.V89.11.3960

Published: 1997

NARROW

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only